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and Peter Burney1*Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is defined by post-bronchodilator spirometry. Data on
“normal values” come predominantly from pre-bronchodilator spirometry. The effects of this on diagnosis are
unknown.
Methods: Lower limits of normal (LLN) were estimated from “normal” participants in the Burden of Obstructive
Lung Disease (BOLD) programme. Values separately derived using pre- and post-bronchodilator spirometry were
compared. Sensitivity and specificity of criteria derived from pre-bronchodilator spirometry and pre-bronchodilator
spirometry adjusted by a constant were assessed in the remaining population. The “gold standard” was the LLN for
the post-bronchodilator spirometry in the “normal population”. For FEV1/FVC, sensitivity and specificity of criteria
were also assessed when a fixed value of < 70% was used rather than LLN.
Results: Of 6,600 participants with full data, 1,354 were defined as “normal”. Mean differences between pre- and
post- bronchodilator measurements were small and the Bland-Altman plots showed no association between
difference and mean value. Compared with using the gold standard, however, tests using pre-bronchodilator
spirometry had a sensitivity and specificity of detecting a low FEV1 of 78.4% and 100%, a low FVC of 99.8% and
99.1% and a low FEV1/FVC ratio of 65% and 100%. Adjusting this by a constant improved the sensitivity without
substantially altering the specificity for FEV1 (99%, 99.8%), FVC (97.4%, 99.9%) and FEV1/FVC (98.7%, 99.5%).
Conclusions: Using pre-bronchodilator spirometry to derive norms for lung function reduces sensitivity compared
to a post-bronchodilator gold standard. Adjustment of these values by a constant can improve validity of the test.
Keywords: Normal values, BOLD study, European populationBackground
GOLD defines chronic pulmonary obstructive disease
(COPD) in terms of post-bronchodilator lung function
[1], but the data from which ‘normal values’ are derived
are generally based on pre-bronchodilator lung function
measures [2,3]. Although some authors have provided
local equations based on post-bronchodilator values or
assessed differences when using bronchodilators [4-6],
there is no general account of the systematic difference
between the two measures. As “normal” values are
derived from “normal” people without overt pathology,* Correspondence: p.burney@imperial.ac.uk
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reproduction in any medium, provided the orit might be anticipated that the differences would be
small and possibly not clinically important.The Burden
of Lung Disease (BOLD) Initiative was designed to de-
velop methodology that can be used to estimate the
prevalence and economic burden of COPD. BOLD is a
survey of COPD among non-institutionalised adults
aged 40 years and over [7]. Study participants complete
a questionnaire covering respiratory symptoms, health
status, activity limitation, and exposure to potential risk
factors, and perform pre- and post-bronchodilator spi-
rometry tests.
This analysis uses BOLD data to estimate the diffe-
rences between pre- and post-bronchodilator measures
and the lower limit of normal values (LLN) derived
using either pre- or post-bronchodilator lung function
measures in the same subjects. We also assessed thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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index and height for males and females, separately,
and the extent of misclassification using criteria based
on pre-bronchodilator spirometry. For FEV1/FVC we
also looked at the extent of misclassification using cri-
teria based on pre-bronchodilator spirometry and de-
fining airway obstruction by FEV1/FVC<70% rather
than <LLN.
Methods
We used BOLD data from the following European
centres: Maastricht (Netherlands), Lisbon (Portugal),
Salzburg (Austria), Bergen (Norway), Krakow (Poland),
Hannover (Germany), Uppsala (Sweden), Reykjavik
(Iceland), Tartu (Estonia) and London (United Kingdom).
Centres were selected to ensure that subjects used in
the analyses were from a population of predominantly
European origin. Spirometry was performed before and
15–60 minutes after inhalation of 200 μg salbutamol
through a spacer. For each participant forced expira-
tory volume in 1 second (FEV1), forced vital capacity
(FVC), forced expiratory volume in 6 seconds (FEV6)
were measured before and after bronchodilator use
and the corresponding FEV1/FVC ratio was calculated.
We selected spirometry data from subjects in good re-
spiratory health (asymptomatic, lifelong non-smokers)
using information from a questionnaire. This included
subjects who lacked respiratory symptoms (wheezing,
phlegm, cough); had no medical diagnosis of asthma,
chronic bronchitis, COPD, or emphysema; and denied
ever having suffered tuberculosis or lung cancer or ha-
ving undergone lung resection. This reference popula-
tion is hereafter refered to as the “normal” population.
To generate predicted and lower limit of normal values,
each of the variables (FEV1, FVC, FEV6, FEV1/FVC) was
entered into a multiple regression model using height,
age and body mass index as predictors. In the regression
models, age was centred by subtracting 40, body mass
index was centred by subtracting 23 whilst height was
centred by subtracting the average height (165 centi-
metres for females and 175 centimetres for males). We
modelled separate regression equations for men and
women for pre- and post-bronchodilator FEV1, FVC,
FEV6, FEV1/FVC. Non-linear relationships were also
investigated by including the square of height and age as
predictors in the models. Models were assessed to deter-
mine whether addition of quadratic terms for age and
height resulted in an improvement in model fit. Likeli-
hood ratio tests were used to compare nested models.
Predicted values and values for the lower limit of
normal (LLN) were estimated for each lung function
variable using these results. The LLN value for each
lung function variable was estimated as LLN value =
predicted value −1.645 * S, where S is an estimate ofthe standard deviation of the residuals and a residual
is the difference between observed and predicted lung
function. Bland-Altman plots were used to examine
the extent of agreement between measured values of
pre- and post-bronchodilator ventilatory function vari-
ables. Bland-Altman plots were also drawn for LLN
values of pre- and post-bronchodilator ventilatory func-
tion variables [8].
For each lung function measurement, differences be-
tween pre- and post bronchodilator measures were
entered into regression models with height, body mass
index and age as predictors to investigate whether there
was an association between the difference and these
predictors. Mean differences between pre- and post
bronchodilator ventilatory function were calculated for
the observed values, the predicted values and the lower
limits of normal together with their 95% limits of
agreement.
Further, for each lung function measurement from
those who had been excluded because they had a smo-
king history, a diagnosis of a history of current respira-
tory symptoms, differences between pre- and post
bronchodilator measures were entered into regression
models with GOLD class (mild, moderate, severe or very
severe) as a predictor to investigate whether there was
association between the difference and the GOLD class.
Finally we used the observed post-bronchodilator ven-
tilatory function from those who had been excluded be-
cause they had a smoking history, a diagnosis or a
history of current respiratory symptoms to estimate the
sensitivity and specificity of using the pre-bronchodilator
LLN or the pre-bronchodilator LLN corrected by a con-
stant which was the mean difference between the pre-
and post-bronchodilator lower limits of normal. These
were then compared with a gold standard of the LLN
estimated directly from the post-bronchodilator ventila-
tory function. Further, for FEV1/FVC we also estimated
sensitivity and specificity using the fixed value of 70% ra-
ther than LLN. In this case we considered the pre-
bronchodilator FEV1/FVC or the pre-bronchodilator
FEV1/FVC corrected by a constant which was the mean
difference between the observed pre- and post-
bronchodilator FEV1/FVC. These were then compared
to a gold standard of using the post-bronchodilator
FEV1/FVC. In addition to sensitivity and specificity we
give Youden’s Index, the sum of sensitivity and specifi-
city −1, a summary validity score that has useful prop-
erties in some circumstances [9]. All statistical analyses
were performed using Stata 12 (Stata Corporation, College
Station, TX USA).
Ethical approval for the study was given in each site
before starting data collection and all participants signed
a consent form after receiving details of the purpose and
content of the study.
Table 2 Number of participants in the study population
from each BOLD site
Variable Men Women
“Normal” population with adequate spirometry
Bergen, Norway 57 73
Hannover, Germany 48 68
Krakow, Poland 29 50
Lisbon, Portugal 49 110
London, England 48 72
Maastricht, Netherlands 46 52
Reykjavik, Iceland 77 56
Salzburg, Austria 133 148
Tartu, Estonia 47 78
Uppsala, Sweden 50 63
“Other”* population with adequate spirometry
Bergen, Norway 242 237
Hannover, Germany 279 235
Krakow, Poland 215 165
Lisbon, Portugal 275 263
London, England 268 275
Maastricht, Netherlands 233 221
Reykjavik, Iceland 320 289
Salzburg, Austria 498 372
Tartu, Estonia 250 216
Uppsala, Sweden 207 186
* Includes smokers and those with respiratory diagnoses or symptoms.
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Table 1 shows the number (%) of subjects excluded for dif-
ferent reasons. Of 7430 participants 830 were omitted from
all analyses because they had inadequate spirometry (746)
or because of missing data (84). Of the 6600 remaining
5246 were excluded from the calculation of normal values
because they had a relevant diagnosis, they smoked or they
complained of respiratory symptoms. These were subse-
quently used to analyse the sensitivity and specificity of the
different criteria. The other 1354 were used to calculate
normal values. Using the spirometric classification of
COPD based on post-bronchodilator FEV1, the distribu-
tion of the 5246 participants (who were excluded from the
calculation of normal values) per GOLD class is; 4053 par-
ticipants have no COPD i.e. FEV1/FVC(%) ≥ 70%, 633
have mild COPD, 461 have moderate COPD, 88 have se-
vere COPD and 11 have very severe COPD.
Table 2 describes the studied population showing the
number of participants included from each BOLD site.
Table 3 describes the studied population, including mean
values of pre- and post- bronchodilator FEV1, FVC,
FEV6 and FEV1/FVC. As expected the “normal” popula-
tion had slightly higher ventilatory function and was
slightly younger. The normal male population was
slightly taller than the other male participants.
Table 4 shows the coefficients and the explained variance
(R2) for the prediction equations for the “normal” popula-
tion. The coefficients for age, age2, (where relevant) and
height are the same whether estimating the mean or the
lower limit of normal. Values are given for each of
the four measures of ventilatory function, pre- and post-
bronchodilator and for each sex separately. The pre- and
post- bronchodilator values for the intercepts are all within
100 mL of each other with the exception of the lower limit
of normal for the FEV1 in men, where the difference is ap-
proximately 125 mL. The pre- and post- bronchodilator
values are often very close to each other and for the FEV6Table 1 Number of subjects excluded*
Total in Sample 37
Excluded for poor quality lung function (%) 3
Incomplete information (cannot be classified)
Total Included 33
Excluded from “normal” population on history* (%) 27
Of whom:
Ever smoked 23
Never-smokers with diagnosis 1
Never-smokers without diagnosis with symptoms 2
Included in “normal population” 5
* Ever Smoked; Diagnosis of asthma, chronic bronchitis, emphysema, lung cancer, C
whistling in the chest in the previous 12 months, cough on most days for as much
that is difficult to bring up when has no cold, troubled by shortness of breath whenthe differences are negligible. Differences in the coefficients
for age and height are also negligible, with the exception of
the values for the FEV1/FVC ratio. The prediction equa-
tions for the FEV1/FVC ratio are relatively poor as is seen
by the much lower R2 value, but the differences between
pre- and post-bronchodilator values are still less than 3%.
Table 5 gives the regression coefficients for the differ-
ence between observed pre- and post-bronchodilatorMale Female Total
93 (100%) 3637 (100%) 7430 (100%)
99 (10.5%) 347 (9.5%) 746 (10.0%)
23 (0.06%) 61 (1.7%) 84 (1.1%)
71 (88.9%) 3229 (88.8%) 6600 (88.8%)
87 (74.1%) 2459 (69.3%) 5246 (70.6%)
53 (62.0%) 1575 (43.3%) 3928 (52.9%)
62 (4.3%) 322 (8.9%) 484 (6.5%)
72 (7.2%) 562 (15.5%) 834 (11.2%)
84 (15.4%) 770 (21.2%) 1354 (18.2%)
OPD, tuberculosis, had part of the lung removed; History of wheezing or
as 3 months each year, usually bringing up phlegm or usually have phlegm
hurrying on the level or walking up a slight hill.
Table 3 Summary of the characteristics of the study
population
Variable Men Women
N Mean SD N Mean SD
“Normal” population with adequate spirometry
Age (years) 584 56.4 12.1 770 57.9 11.7
Height (cm) 584 176.5 7.8 770 162.2 7.1
pre- BD FEV1 (litres) 584 3.58 0.78 770 2.52 0.56
pre- BD FEV6 (litres) 584 4.55 0.91 770 3.19 0.68
pre- BD FVC (litres) 584 4.76 0.91 770 3.32 0.69
pre- BD FEV1/FVC (%) 584 75.1 6.6 770 75.9 6.1
post-BD FEV1 (litres) 584 3.67 0.77 770 2.58 0.57
post-BD FEV6 (litres) 584 4.55 0.88 770 3.19 0.67
post-BD FVC (litres) 584 4.71 0.88 770 3.29 0.68
post-BD FEV1/FVC (%) 584 77.9 6.3 770 78.5 6.0
“Other”* population with adequate spirometry
Age (years) 2787 58.7 11.3 2459 58.7 11.7
Height (cm) 2787 175.4 7.4 2459 162.2 7.3
pre- BD FEV1 (litres) 2787 3.19 0.84 2459 2.34 0.63
pre- BD FEV6 (litres) 2787 4.18 0.96 2459 3.03 0.73
pre- BD FVC (litres) 2787 4.43 0.97 2459 3.19 0.75
pre- BD FEV1/FVC (%) 2787 71.5 9.2 2459 72.9 8.6
post-BD FEV1 (litres) 2787 3.29 0.84 2459 2.41 0.63
post-BD FEV6 (litres) 2787 4.21 0.93 2459 3.05 0.71
post-BD FVC (litres) 2787 4.43 0.94 2459 3.08 0.73
post-BD FEV1/FVC (%) 2787 73.9 9.4 2459 75.6 8.9
* Includes smokers and those with respiratory diagnoses or symptoms.
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bronchodilator values) for the “normal population”. The
intercept represents the mean difference between the
two measurements at age 40 years, body mass index 23
and average height. For FEV1 these mean levels
increased significantly post-bronchodilator (91 ml (95%
CI: 64, 117) for men and 77mL (95% CI: 63, 92) for
women), for FEV1/FVC the mean levels also increased
significantly post-bronchodilator (2.35% (95% CI: 1.76,
2.93) for men and 2.94% (95% CI: 2.43, 3.45) for
women. In contrast the FVC fell significantly by 46 mL
(95% CI : 7, 86) in men and by 47 mL (95% CI: 21, 72)
in women. The regression coefficients for age, body
mass index and height show negligible associations
which are for the most part not significant. Further, a
random intercept model (a regression model with a
separate intercept for each centre) showed no evidence
of between-centre heterogeneity, suggesting that the
results are similar in each of the centres included in
the study. For the “non-normal” population the differ-
ences between pre- and post-bronchodilator were: FEV1
in women with mild disease was 59mL (95% CI: 9, 109)
greater than those with severe disease; FVC in men
with severe disease was 95mL (95% CI: 10, 177) greaterthan those with mild disease; FVC in men with very se-
vere disease was 275mL (95% CI: 60, 490) greater than
those with mild disease; FEV6 in men with very severe
disease was 176mL (95% CI: 20, 332) greater than those
with mild disease; FEV1/FVC in men with moderate
disease was 0.9% (95% CI: 0.29%, 1.52%) greater than
those with mild disease.
Table 6 shows the mean differences and 95% limits of
agreement for the observed values, the predicted values
and the lower limits of normal. The mean observed dif-
ferences and the predicted differences are equal, by def-
inition, but the limits of agreement are much narrower
for the predicted values, as expected.
Table 7 gives the sensitivity and specificity of using the
pre-bronchodilator values and the pre-bronchodilator
values adjusted with a fixed constant when compared with
the gold standard of using the calculated lower limits of
normal using the post-bronchodilator values. The data
used to estimate these come from the participants
excluded from the “normal” population, and therefore do
not include individuals who were used to estimate the ori-
ginal norms. Compared with the “gold standard” of the
lower limit of normal derived from post-bronchodilator
spirometry, use of the pre-bronchodilator LLN criterion
results in a substantially lower sensitivity when judging an
abnormal FEV1 (sensitivity =78.4%) or FEV1/FVC ratio
(sensitivity = 65%), though specificity remains high. Chan-
ging the LLN based on the pre-bronchodilator spirometry
with an added constant improves the characteristic of the
tests overall and the Youden’s index is above 0.95 for all
measures. Table 8 gives the sensitivity and specificity of
using the pre-bronchodilator values and the pre-
bronchodilator values adjusted with a fixed constant when
compared with the gold standard of using the post-
bronchodilator values when using the fixed cut off of 70%
as the criterion for a low FEV1/FVC. In this case adding a
constant lowers Youden’s Index and sensitivity, but
increases the specificity of the test.
Bland-Altman plots for the two sexes show no obvious
relation between the difference and magnitude of FEV1,
FEV6, FVC and FEV1/FVC (%), respectively. (Figure 1). The
mean differences between pre- and post-bronchodilator
values for measured FEV1, FVC, FEV6 and FEV1/FVC are
76 mL (95% CI 69, 83 ), -38 mL (95% CI −48, -27), 1.6 mL
(95% CI −6.6, 9.8 ) and 2.66% (95% CI 2.47, 2.85),
respectively.
Figure 2 gives similar plots for the lower limits of nor-
mal. The mean differences between pre- and post-
bronchodilator values for the LLN of FEV1, FVC, FEV6
and FEV1/FVC are 92 mL (95% CI 91, 94 ), -27 mL (95%
CI −28, -26 ), 9.54 mL (95% CI 8.44, 10.64 ) and 2.91%
(95% CI 2.88, 2.94), respectively. All of the above differ-
ences are adjusted for age, height and sex. It is clear that
the distribution of the difference is irregular with respect
Table 4 Regression coefficients for lung function values against age, height and body mass index for each sex and for
both pre- and post-bronchodilator values
Pre/Post Broncho-dilator Sex Intercept (mean)* Intercept (LLN)* Age Age squared Height BMI R2
FEV1 (L) Pre M 4.153 3.353 −0.034 0.039 −0.02 0.61
Post M 4.244 3.475 −0.034 0.039 −0.02 0.63
Pre F 3.123 2.564 −0.028 0.029 −0.009 0.64
Post F 3.201 2.648 −0.028 0.029 −0.01 0.65
FVC (L) Pre M 5.293 4.322 −0.031 0.055 −0.029 0.58
Post M 5.247 4.297 −0.031 0.053 −0.03 0.58
Pre F 3.991 3.287 −0.028 0.043 −0.017 0.62
Post F 3.944 3.242 −0.027 0.042 −0.016 0.61
FEV6 (L) Pre M 5.171 4.272 −0.036 0.054 −0.031 0.64
Post M 5.142 4.262 −0.034 0.052 −0.029 0.63
Pre F 3.892 3.238 −0.030 0.04 −0.016 0.65
Post F 3.879 3.225 −0.029 0.04 −0.016 0.65
FEV1/FVC (%) Pre M 78.407 68.626 −0.102 −0.00359 −0.062 0.19
Post M 80.883 71.563 −0.085 −0.00362 −0.048 0.19
Pre F 77.876 68.782 −0.041 −0.00446 −0.172 0.105 0.17
Post F 80.818 71.811 −0.013 −0.00532 −0.119 0.18
*for men aged 40 years, with body mass index 23 and 175 centimetres tall and women aged 40 years, with body mass index 23 and 165 centimetres tall.
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is different for each sex and each measurement.
Plots of residuals (Figures 3 and 4) for pre- and post-
bronchodilator FEV1, FVC, FEV6 and FEV1/FVC against
the corresponding predicted values reveal a pileup of
residuals in the centre of the plot at each predicted value
and a normal distribution of residuals trailing offTable 5 Regression of difference between observed pre- and
bronchodilator – pre-bronchodilator values) in millilitres
Men
Covariate Regression coefficient 95% confide
FEV1 (mL) Intercept * 90.61 (64.14,
Age/year 0.033 (−1.07
Height/cm 0.23 (−1.47
BMI −0.15 (−3.66
FEV6 (mL) Intercept * −29.31 (−59.3
Age/year 1.47 (0.22
Height/cm −1.66 (−3.58
BMI 1.99 (−1.99
FVC (mL) Intercept * −46.16 (−85.73
Age/year 0.15 (−1.49
Height/cm −2.50 (−5.04
BMI −0.35 (−5.60
FEV1/ FVC (%) Intercept * 2.35 (1.76
Age/year 0.016 (−0.008
Height/cm 0.015 (−0.022
BMI 0.036 (−0.041
*Difference at age 40 years, body mass index 23 and 175 centimetres height in mesymmetrically from the centre. Further the band enclos-
ing the residuals is approximately equal across the range
of predicted values). This shows that the assumptions of
normality and homoscedasticity are met and implies that
it is reasonable to estimate the fifth percentile of lung
function (LLN) of each subject by subtracting 1.645*S
from a subject’s predicted value.post-bronchodilator lung function values (post
Women
nce interval Regression coefficient 95% confidence interval
117.08) 77.47 (62.90, 92.04)
, 1.13) −0.31 (−1.01, 0.39)
, 1.93) 1.82 (0.66, 3.00)
, 3.37) −0.81 (−2.57, 0.95)
2, 0.71) −12.95 (−31.88, 5.98)
, 2.71) 0.79 (−0.12, 1.70)
, 0.27) −0.10 (−1.62, 1.42)
, 5.97) 0.52 (−1.76, 2.81)
, -6.58) −46.65 (−72.37, -20.94)
, 1.80) 0.70 (−0.54, 1.93)
, 0.04) −1.56 (−3.62, 0.51)
, 4.90) 0.26 (−2.85, 3.36)
, 2.93) 2.94 (2.43, 3.45)
, 0.040) −0.007 (−0.031, 0.018)
, 0.053) 0.064 (0.023, 0.105)
, 0.113) −0.017 (−0.078, 0.045)
n or 165 centimetres height in women.
Table 6 Pre- and post- bronchodilator differences (in millilitres) between observed spirometric values, predicted values
and lower limits of normal values for men and women
Men Women
Mean difference 95% limits of agreement Mean difference 95% limits of agreement
FEV1 (L) Observed 91 (−203, 385) 64 (−145, 273)
Predicted 91 (88, 94) 64 (34, 95)
LLN 121 (118, 124) 69 (39, 101)
FEV6 (L) Observed −0.37 (−338, 337) 3.1 (−267, 273)
Predicted −0.37 (−53, 52) 3.1 (−17, 23)
LLN 18 (−31, 71) 3 (−15.7, 22.7)
FVC (L) Observed −49 (−491, 393) −29 (−396, 338)
Predicted −49 (−89, 9) −29 (−61, 3)
LLN −28 (−68,12) −27 (−59, 5)
FEV1/FVC (%) Observed 2.76 (−3.73, 9.25) 2.59 (−4.73, 9.91)
Predicted 2.76 (2.41, 3.11) 2.59 (1.27, 3.91)
LLN 3.22 (2.87, 3.57) 2.68 (1.36, 4.00)
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As expected, the observed value of lung function in a
“normal” population changes little with the use of a bron-
chodilator and differences between centres were not sig-
nificant. The case for the predicted and for the lower limit
of normal is more complicated, although the mean differ-
ence is the same for the predicted as for the observed, by
definition, and similar in magnitude for the lower limit of
normal. This analysis has shown that, although the pre-
bronchodilator lower limit of normal for the lung function
test is a reasonable approximation to the lower limit of
normal, using pre-bronchodilator norms substantially
reduces the sensitivity of spirometry in identifying cases of
chronic airflow limitation. Addition of a fixed amount
provides an even more nearly approximate value to the
true post-bronchodilator “normal” values, raising sensitiv-
ity to over 99%.
Although it is inconsistent to use pre-bronchodilator
“normal values” to assess post-bronchodilator responsesTable 7 Sensitivity and Specificity of using the pre-bronchodi
bronchodilator lower limit of normal with an added constant
the post bronchodilator values
<LLN using pre-bronchodilator
Sensitivity Specificity Youden’s ind
FEV1 78.4% 100% 0.78
FEV6 96.1% 100% 0.96
FVC 99.8% 99.1% 0.99
FEV1/FVC 65.0% 100% 0.65
Results for 5246 subjects in the “non-normal” survey population. The participants in
estimation of normal values because of a history of smoking or of respiratory diagn
Values of “K”.
for FEV1 (mLs): 121 (men); 69 (women).
for FEV6 (mLs): 18 (men); 3 (women).
for FVC (mLs): -29 (men); -27 (women).
for FEV1/FVC (%) : 3.22 (men); 2.68 (women).the similarity of results using either method is not sur-
prising. Resting tone in the normal airway is low and
the effect of a bronchodilator is likely to be similarly
small. These data come from a study with a very high
level of quality assurance and with a strong training
programme for the technicians prior to starting the
programme.
Estimating predicted values produced a reasonable fit
and similar parameter estimates using either the pre- or
post- bronchodilator results. Comparing the observed
results using either method showed small average differ-
ences between pre- and post- bronchodilator results and
no discernable variation in the difference with respect to
the average of the pre- and post-bronchodilator values.
The changes in lung function observed in the “normal”
population following bronchodilator are, as expected,
small. The small fall in FVC was not predicted but the size
of the fall is small and may be due to tiring of the partici-
pants. If so, it is part of the usual post-bronchodilator testlator lower limit of normal and using the pre-
compared with the lower limit of normal derived from
<LLN using pre-bronchodilator + K
ex Sensitivity Specificity Youden’s index
99% 99.8% 0.99
98% 99.8% 0.98
97.4% 99.9% 0.97
98.7% 99.5% 0.98
cluded were those with adequate spirometry, but excluded from the
osis or symptoms.
Table 8 Sensitivity and Specificity of using the pre-bronchodilator and using the pre-bronchodilator with an added
constant compared with the post-bronchodilator values
<70% using pre-bronchodilator <70% using pre-bronchodilator + K
Sensitivity Specificity Youden’s index Sensitivity Specificity Youden’s index
FEV1/FVC 90% 85% 0.75 79% 94% 0.73
Results for 5246 subjects in the “non-normal” survey population. The participants included were those with adequate spirometry, but excluded from the
estimation of normal values because of a history of smoking or of respiratory diagnosis or symptoms.
Values of “K”: 2.76 (men); 2.59 (women).
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out bronchodilator. The Bland-Altman plots for the pre-
dicted values (not shown), and hence also the values for
the lower limits of normal, are less satisfactory and show
variable associations between mean difference and average
value for the different measurements. This in part reflects
the observation that the difference is not a constant but
varies also by age and height (Table 5). Nevertheless the
limits of agreement are narrow, for FEV1 lying between ±
3.5 mL (men), and ± 31 mL (women); for FEV6: ±53 mL
(men), ±20 mL (women); for FVC ± 40 mL (men), ±
32 mL (women); for FEV1/FVC: ± 0.35% (men) ± 1.32%
(women).
The data come from a large multi-centric study of
general population samples over the age of 40 years, andFigure 1 Bland Altman plots for observed FEV1, FEV6, FVC and FEV1/
the mean difference between pre- and post bronchodilator measured lungthe sites chosen were inhabited by people of predomin-
antly European origin. Younger populations have a
greater tendency to reversible airway obstruction and al-
though the extent of this in people with neither respira-
tory symptoms nor respiratory diagnoses is likely to be
more limited, we cannot extrapolate our findings to
younger age groups. Nor can we extrapolate the findings
to other ethnic groups, though again the findings are
likely to be similar as there are unlikely to be large varia-
tions in resting tone in normal airways in different eth-
nic groups. Within this population the findings were
similar in each of the centres included.
In the BOLD study bronchodilation is achieved by
administering 200μg salbutamol via a spacer. The GOLD
convention is to give a 400μg dose. The BOLD decisionFVC (males – solid circles, females – hollow circles). The lines show
function for males (solid line) and females (dotted line).
Figure 2 Bland Altman plots for LLN values of FEV1, FEV6, FVC and FEV1/FVC (males – solid circles, females – hollow circles). The lines
show the mean difference between pre- and post bronchodilator LLN values for males (solid line) and females (dotted line).
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great an effect as 400μg [10] and provides a more ac-
ceptable profile of side effects for a population survey of
volunteer participants with much less likelihood of hav-
ing ever used a bronchodilator before. We believe that
an additional 200μg of salbutamol would have achieved
very little additional change in this group of participants.
In epidemiological studies it is not always necessary or
even desirable to divide a population into “diseased” and
“healthy”, and ventilatory function can be treated as a con-
tinuous variable. However, where a binary variable is
required, as it is, for instance, when making a diagnosis,
and hence when estimating a prevalence, there is a need
to decide on the cut-off point between the normal and ab-
normal. In many clinical situations this is done by estimat-
ing the 95% tolerance limits in the “normal population”.
This is however an arbitrary criterion and is agreed by
convention. There is no clinical reason for not using a
slightly stricter or more relaxed criterion if this is more
convenient. There is a great deal of information collected
from around the world on “normal” ventilatory function
based on this method [11]. The principles underlying this
collection have been similar for many years, though the
operational definitions of “normal” participants havevaried. Nevertheless almost all studies have been con-
ducted without the use of a bronchodilator, which is es-
sential in the use of the test to define COPD according to
international guidelines. Given the arbitrary nature of the
conventions for defining “normal” values, including the
choice of the 95% tolerance limits and the decision on
whom to include as “normal” or exclude as potentially ab-
normal, the differences introduced by using pre- rather
than post- bronchodilator ventilatory function, though
substantial, are not large. Providing that they are used
consistently use of norms based on pre-bronchodilator
spirometry are probably acceptable for most purposes. It
is, by contrast, very important that the test itself is admi-
nistered with a bronchodilator, and this is still not the
usual practice in prevalence surveys.
In epidemiological studies we recommend the use of
the lower limit of normal as the criterion for a low
FEV1/FVC ratio as this is the most convenient way to
adjust prevalence to age. Nevertheless some arguments
are still made for the fixed ratio of 70% and this remains
the recommendation of GOLD. Mannino has argued
that as the lower limit of normal is less sensitive than
the fixed ratio, which is the case at least over the age of
about 45 years, that its use leads to “under-diagnosis” of
Figure 3 Plots of residuals versus predicted values for pre-bronchodilator lung function.
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diagnosis is not a concern. A Dutch study in Primary
Care has also reported that the fixed ratio gives a more
accurate assessment of disease when compared to clin-
ical opinion in diagnosing clinical COPD [13]. As in
other reports the fixed ratio was more sensitive and less
specific than the lower limit of normal and in a lower
prevalence environment would have come to the oppos-
ite conclusion. As the Fixed Ratio is still used we have
provided results for this criterion also.
In the absence of a large set of observations on post-
bronchodilator ventilatory function, the options for de-
fining “abnormal” values are, effectively, three. First, and
easiest, the pre-bronchodilator norms can be used. As
bronchodilators have little effect in the absence of smok-
ing, diagnoses and symptoms, this is not a bad approxi-
mation and, as the choice of a 95% cut off for the
“normal value” is in any case arbitrary, it is adequate at
least where only internal comparisons are being made,
or where the comparisons are made with studies that
have made similar assumptions. Second, the estimates
can be changed by a fixed amount to take account of the
small average difference induced by the bronchodilator
in normal people. As the bronchodilator has slightly dif-
ferent effects on normal subjects according to their age,
sex and height, this will not provide a perfect solutionand there will be a small distortion in the estimate which
will vary by these characteristics. The effect is however
small and not of clinical significance when using the
lower limit of normal. It should be noted that the small
correction added here is based on the BOLD data and
needs to be tested in other populations, but it gives
some idea of the size of the correction and its ability to
adjust adequately for the use of pre-bronchodilator stan-
dards. It is notable that the addition of this constant did
not improve the results for the test based on the fixed
ratio, as judged by Youden’s index. This is likely to be
due to the greater distortion induced when adding a
constant where age has not been adjusted for. Third, in-
ternal estimates of normal values can be estimated from
the post-bronchodilator measurements taken in the
study itself on “normal” participants. This last option is
clearly not available to clinical studies and it has the dis-
advantage in epidemiological studies that the estimates
will almost always be determined on relatively small
samples, which makes them inherently unreliable.
Conclusions
Using different predictors of normal lung function based
on pre- or post- bronchodilator spirometric values pro-
vides slightly different results, but these may not be of
great clinical significance provided they are used
Figure 4 Plots of residuals versus predicted values for post-bronchodilator lung function.
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http://respiratory-research.com/content/13/1/102consistently in comparative studies. In a clinical setting
spirometry should be used in combination with other in-
formation to guide management and these small differ-
ences are unlikely to be important when setting criteria
for a positive screening test if this is based on a pre-
bronchodilator assessment of spirometry. We have pro-
vided prediction equations for post-bronchodilator lung
function in people over the age of 40 years living in
Europe. We have also provided approximate mean dif-
ferences between pre-and post-bronchodilator values
and we have given estimates of the effect of using the
different methods on sensitivity and specificity of a test
for COPD.
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